Literature DB >> 28533654

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI.

Amarnath Jena1, Shuaib Zaidi2, Vikas Kashyap3, Abhishek Jha1, Sangeeta Taneja1.   

Abstract

PSMA PET is increasingly being used in imaging of recurrent prostate carcinoma. A case with suspected recurrent Prostate carcinoma (PCa), raised PSA (Prostate specific antigen) and suspected spinal metastases was referred for whole body Ga-68-PSMA PET/MRI. The study revealed PSMA avid recurrent prostate mass and extensive osseous metastases. Abnormal PSMA uptake in the thyroid gland prompted USG-guided FNAC which revealed Hurthle cell neoplasm. Histopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative.

Entities:  

Keywords:  Hurthle cell adenoma; PET/MRI; PSMA; prostate carcinoma; thyroid carcinoma

Year:  2017        PMID: 28533654      PMCID: PMC5439198          DOI: 10.4103/0972-3919.202248

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


Case report

A 66-year-old male with the history of prostate carcinoma, who underwent transurethral resection of the prostate 2 years back with raised PSA level and suspected spinal metastases, was referred for Ga-68-PSMA whole-body simultaneous PET/MRI scan for restaging. A bulky T2W hypointense mass was noted in residual prostate involving right seminal vesicle [Figure 1a] with the base of the bladder and mesorectal fascia, showing diffusion restriction [Figure 1b and 1c], increased Ktrans [Figure 1d] and increased PSMA uptake SUV max = 12.1 to 21.1 [Figure 1e and 1f]. No enlarged/PSMA avid nodes were seen. Widespread PSMA avid marrow lesions were seen extensively involving the spine [Figure 1g and 1h] and the remaining skeleton with SUV max = 8.5 to 27.5 [Figure 1i].
Figure 1

Representative PET/MRI images of a bulky hypointense mass (a) axial T2 is noted in residual prostate showing diffusion restriction (b) DWI with b = 800 and (c) ADC, (d) increased Ktrans and (e) increased PSMA uptake (f) fused PET/MRI. No enlarged/PSMA avid nodes were seen. Sagittal STIR (g) and fused PET/MRI (h) images showing PSMA avid marrow lesions. MIP PET (i) image showing wide spread PSMA avid metastases in the remaining skeleton.

Representative PET/MRI images of a bulky hypointense mass (a) axial T2 is noted in residual prostate showing diffusion restriction (b) DWI with b = 800 and (c) ADC, (d) increased Ktrans and (e) increased PSMA uptake (f) fused PET/MRI. No enlarged/PSMA avid nodes were seen. Sagittal STIR (g) and fused PET/MRI (h) images showing PSMA avid marrow lesions. MIP PET (i) image showing wide spread PSMA avid metastases in the remaining skeleton. Further, an enlarged thyroid gland showing multiple nodules of varying intensity and sizes involving both lobes [Figure 2a–2c] was observed with focal increased PSMA uptake [Figure 2d–2f] on the left side with SUV max = 5.9. No enlarged/ PSMA avid nodes were seen in bilateral neck.
Figure 2

Representative PET/MRI image of an enlarged thyroid gland showing multiple nodules (a-c) axial T1; T2 and sagittal STIR respectively and focal areas of PSMA uptake (d-f) axial PET; axial fused PET/MRI and sagittal fused PET/MRI respectively.

Representative PET/MRI image of an enlarged thyroid gland showing multiple nodules (a-c) axial T1; T2 and sagittal STIR respectively and focal areas of PSMA uptake (d-f) axial PET; axial fused PET/MRI and sagittal fused PET/MRI respectively. USG-guided FNAC of thyroid was done which was reported as Hurthle cell neoplasm. Subsequently, total thyroidectomy was performed and the excised gland was sent for HPE which revealed multiple large nodules in both lobes consistent with Hurthle cell adenoma [Figure 3a]. In addition, small sub centimeter foci showing tubule-papillary architecture of papillary carcinoma [Figure 3b] were also noted in both lobes of thyroid. Subsequently, immunohistochemistry analysis was carried out and the thyroid lesions were found to show intense expression for thyroglobulin [Figure 3c] and no expression for PSA [Figure 3d] thereby ruling out metastases from PCa and proving that it is a primary thyroid neoplasm. A small pretracheal node sampled during surgery was reported to have metastases from papillary thyroid carcinoma based on its follicular architecture [Figure 3e and 3f]. The pretracheal node was positive for thyroglobulin and negative for PSA [Figure 3g and 3h]. Central compartment neck lymph nodes showed no evidence of metastases. There was no lymphovascular, perineural, capsular invasion and extension into the perithyroidal soft tissue associated with any of the tumors.
Figure 3

Histopathological examination showed (a) multiple large nodules in both lobes consistent with Hurthle cell adenoma, 10X, comprising of microfollicles lined by cuboidal cells showing abundant deeply eosinophilic cytoplasm. (b) Sub centimeter foci showing tubule-papillary architecture of papillary carcinoma (10X). (c,d) Immunohistochemistry analysis in thyroid lesions showing intense expression for thyroglobulin (10X) and no expression for PSA (10X). (e,f) A small pretracheal metastatic node from papillary thyroid carcinoma (4X and 10X respectively). (g,h) The node showed positive expression for thyroglobulin (10X) and negative expression for PSA negative (4X).

Histopathological examination showed (a) multiple large nodules in both lobes consistent with Hurthle cell adenoma, 10X, comprising of microfollicles lined by cuboidal cells showing abundant deeply eosinophilic cytoplasm. (b) Sub centimeter foci showing tubule-papillary architecture of papillary carcinoma (10X). (c,d) Immunohistochemistry analysis in thyroid lesions showing intense expression for thyroglobulin (10X) and no expression for PSA (10X). (e,f) A small pretracheal metastatic node from papillary thyroid carcinoma (4X and 10X respectively). (g,h) The node showed positive expression for thyroglobulin (10X) and negative expression for PSA negative (4X).

Discussion

PSMA based simultaneous PET/MRI is a novel imaging technique which has been used in diagnosis of recurrent prostate carcinoma.[1] PSMA uptake has been demonstrated in both non-prostatic neoplastic[23456] and non-neoplastic lesions.[78] PSMA uptake is also seen in both benign[9] and malignant neoplasms of thyroid.[101112] Although rare, metastatic spread to the thyroid gland from primary PCa has been reported in the past.[1314] In this patient, metastases to the thyroid was a distinct possibility in view of widespread metastatic disease not observed in this case. So, in a case of PSMA avid thyroid lesion, it is important to differentiate metastases with primary thyroid neoplasm with biopsy before initiating further treatment.

Financial support and sponsorship

Nil

Conflicts of interest

There are no conflicts of interest
  14 in total

1.  (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.

Authors:  Arun Sasikumar; Ajith Joy; Raviteja Nanabala; M R A Pillai; Boben Thomas; K R Vikraman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-08       Impact factor: 9.236

2.  Prostate cancer metastasis to thyroid gland.

Authors:  Hadi Selimoglu; Cevdet Duran; Ozlem Saraydaroglu; Metin Guclu; Sinem Kiyici; Canan Ersoy; Mehmet All Eren; Ercan Tuncel; Sazi Imamoglu
Journal:  Tumori       Date:  2007 May-Jun       Impact factor: 2.098

3.  PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?

Authors:  Sameer Kamalakar Taywade; Nishikant Avinash Damle; Chandrasekhar Bal
Journal:  Clin Nucl Med       Date:  2016-05       Impact factor: 7.794

4.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

5.  Incidental Detection of Follicular Thyroid Carcinoma in 68Ga-PSMA PET/CT Imaging.

Authors:  Sait Sager; Betül Vatankulu; Lebriz Uslu; Kerim Sönmezoglu
Journal:  J Nucl Med Technol       Date:  2016-03-10

6.  Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis.

Authors:  Carsten Kobe; David Maintz; Thomas Fischer; Alexander Drzezga; De-Hua Chang
Journal:  Clin Nucl Med       Date:  2015-11       Impact factor: 7.794

7.  Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.

Authors:  Gowri L Kanthan; James Drummond; Geoff Paul Schembri; Michael A Izard; Edward Hsiao
Journal:  Clin Nucl Med       Date:  2016-04       Impact factor: 7.794

8.  Isolated multiple bilateral thyroid metastases from prostatic adenocarcinoma: case report and literature review.

Authors:  Nader M Albsoul; Fatima N Obeidat; Azmy M Hadidy; Mohammad N Alzoubi; Abtehag A Taib; Awni D Shahait
Journal:  Endocr Pathol       Date:  2013-03       Impact factor: 3.943

9.  Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Authors:  Natsuko Nomura; Sandra Pastorino; Pengfei Jiang; Gage Lambert; John R Crawford; Marco Gymnopoulos; David Piccioni; Tiffany Juarez; Sandeep C Pingle; Milan Makale; Santosh Kesari
Journal:  Cancer Cell Int       Date:  2014-03-20       Impact factor: 5.722

10.  Uptake of 18F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies.

Authors:  Steven P Rowe; Curtiland Deville; Channing Paller; Steve Y Cho; Elliot K Fishman; Martin G Pomper; Ashley E Ross; Michael A Gorin
Journal:  Tomography       Date:  2015-12
View more
  6 in total

1.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

2.  Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center.

Authors:  Marceline W Piek; Lisa H de Vries; Maarten L Donswijk; Bart de Keizer; Jan Paul de Boer; Lutske Lodewijk; Rachel S van Leeuwaarde; Menno R Vriens; Koen J Hartemink; Iris M C van der Ploeg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-15       Impact factor: 10.057

Review 3.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

Review 4.  Recent Development of Nuclear Molecular Imaging in Thyroid Cancer.

Authors:  Huiting Liu; Xiaoqin Wang; Ran Yang; Wenbing Zeng; Dong Peng; Jason Li; Hu Wang
Journal:  Biomed Res Int       Date:  2018-05-21       Impact factor: 3.411

5.  PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome.

Authors:  Martina Sollini; Luca di Tommaso; Margarita Kirienko; Chiara Piombo; Marco Erreni; Andrea Gerardo Lania; Paola Anna Erba; Lidija Antunovic; Arturo Chiti
Journal:  EJNMMI Res       Date:  2019-10-15       Impact factor: 3.138

6.  Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.

Authors:  Dharmender Malik; Apurva Sood; Bhagwant Rai Mittal; Harmandeep Singh; Rajender Kumar Basher; Jaya Shukla; Anish Bhattacharya; Shrawan Kumar Singh
Journal:  Indian J Nucl Med       Date:  2018 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.